Cipla Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has ninety-two approved drugs.
There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and thirty-nine supplementary protection certificates in seventeen countries.
Summary for Cipla
| International Patents: | 30 |
| US Patents: | 6 |
| Tradenames: | 81 |
| Ingredients: | 81 |
| NDAs: | 92 |
| Patent Litigation for Cipla: | See patent lawsuits for Cipla |
| PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | PHYTONADIONE | phytonadione | INJECTABLE;INJECTION | 212424-002 | Apr 22, 2022 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Cipla | DARUNAVIR | darunavir | TABLET;ORAL | 206288-002 | Nov 28, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cipla | DIMETHYL FUMARATE | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 210305-002 | Sep 24, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cipla | ISOPROTERENOL HYDROCHLORIDE | isoproterenol hydrochloride | INJECTABLE;INJECTION | 211738-001 | Jun 28, 2019 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 2217610 | ⤷ Try a Trial |
| China | 101516370 | ⤷ Try a Trial |
| South Korea | 101296099 | ⤷ Try a Trial |
| European Patent Office | 2083823 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cipla Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0817637 | C00817637/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ABACAVIR + LAMIVUDIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 56977 31.10.2005 |
| 2435024 | 2021C/518 | Belgium | ⤷ Try a Trial | PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210 |
| 2487163 | 1790002-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/15/1025, 2015-07-15 |
| 2435024 | LUC00208 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
